[A25-18] Sarilumab (polymyalgia rheumatica) – Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2025
Project no.:
A25-18
Commission:
Commission awarded on 04.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Adults with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper
- Patients for whom corticosteroids are the appropriate treatment of physician’s choice: added benefit not proven
- Patients for whom the combination of corticosteroids with methotrexate is the appropriate treatment of physician’s choice: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-18
| Project no. | Title | Status |
|---|---|---|
| A17-39 | Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-19 | Sarilumab (polyarticular juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |